Shanghai Pharmaceuticals Holding Co., Ltd. (02607.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 10.75

From 52W high−13.70%

Volume5.42M

Market capHKD 39.94B

P/E (TTM)7.3x

P/S (TTM)0.1x

Div yield6.07%

Key dataSep 18, 2026

Open

HKD 10.75

From 52W high

−13.70%

Volume

5.42M

Market cap

HKD 39.94B

ValuationView details →

P/E (Fwd)

7.2x

EV/EBITDA

7.9x

P/E (TTM)

7.3x

RSI (14)

28.6

MomentumView details →

1D Return

−0.74%

YTD Return

−5.36%

ValuationView details →

P/E (Fwd)

7.2x

P/E (TTM)

7.3x

EV/EBITDA

7.9x

EV/Sales

0.2x

P/S (TTM)

0.1x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

10.81%

Net Margin

1.65%

EBITDA Margin

3.01%

ROE (TTM)

6.06%

ROA (TTM)

1.97%

Asset Turnover

1.21x

GrowthView details →

Revenue YoY

+3.97%

EPS YoY

−22.09%

FCF YoY

+302.04%

Revenue CAGR 3Y

+6.92%

EPS CAGR 3Y

−1.47%

EBITDA YoY

−7.32%

MomentumView details →

1D Return

−0.74%

YTD Return

−5.36%

1Y Return

−12.65%

RSI (14)

28.6

vs 50D SMA

−7.50%

vs 200D SMA

−8.16%

Capital & dividendView details →

Debt/Equity

0.84x

Current Ratio

1.34x

Quick Ratio

1.04x

Div Yield

6.07%

Div Rate

HKD 0.65

Div Growth 1Y

+16.09%

EarningsView details →

EPS (Actual)

HKD 0.76

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.30

Avg Surprise (4Q)

0.00%

Rev Surprise

−4.85%

Financials snapshotView financials →

Revenue (TTM)

288.45B

Net Income (TTM)

4.75B

Op. CF (TTM)

9.91B

Next earningsOct 23, 2026 →

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago

Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago

Similar companies

Sinopharm Group Co. Ltd.01099.HK Cardinal Health, Inc.CAH Cencora, Inc.COR XD上海医601607.SH 九州通600998.SH 国药股份600511.SH Find similar companies →

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.27d ago